Global Gastrointestinal Stromal Tumors Therapeutics Market Growth (Status and Outlook) 2025-2031

The global Gastrointestinal Stromal Tumors Therapeutics market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022.

In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.

The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs.

However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations.

Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need.

Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

ReportPrime' newest research report, the “Gastrointestinal Stromal Tumors Therapeutics Industry Forecast” looks at past sales and reviews total world Gastrointestinal Stromal Tumors Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Gastrointestinal Stromal Tumors Therapeutics sales for 2025 through 2031.

This Insight Report provides a comprehensive analysis of the global Gastrointestinal Stromal Tumors Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.

This report also analyses the strategies of leading global companies with a focus on Gastrointestinal Stromal Tumors Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Gastrointestinal Stromal Tumors Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gastrointestinal Stromal Tumors Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity.

Segmentation by Type:

• Oral
• Non-oral

Segmentation by Application:

• Hospital
• Clinic
• Others

This report also splits the market by region:

Americas

• United States
• Canada
• Mexico
• Brazil

APAC

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

Europe

• Germany
• France
• UK
• Italy
• Russia

Middle East & Africa

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Companies coverage:

• Ascentage Pharma Group International
• Bayer AG
• Blueprint Medicines Corp
• Bristol Myers Squibb Co.
• Deciphera Pharmaceuticals Inc
• Immunicum AB
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Xencor Inc.

Key Questions Addressed in this Report: